



**HIV**  
FROM  
A to Z

Training the new  
**generation of HIV**  
physicians

## ACCREDITATION



The **HIV from A to Z - Module 1, 2, 3, 4 and 5** organized by FLS Science, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME is an institution of the European Union of Medical Specialists (UEMS). Only those e-learning materials that are displayed on the UEMSEACCME website have formally been accredited.

Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

An application of this e-learning activity has been made to the **UEMS EACCME®** for CME accreditation.

## MORE INFORMATION

[www.fls-science.com](http://www.fls-science.com)



## SCIENTIFIC COMMITTEE

### Josep M. Llibre

Fight Infections Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, Spain

### Monica Gandhi

University California San Francisco, CA, USA

### Pedro Cahn

Fundación Huésped, Buenos Aires, Argentina

### Chloe Orkin

Queen Mary University of London, United Kingdom

With the scientific support of:



**EACS** European  
AIDS Clinical Society



FUNDACIÓN  
**HUÉSPED**  
PREVENCIÓN-CIENCIA-DERECHOS



**HIV**  
FROM  
A to Z

Training the new  
**generation of HIV**  
physicians

Month	Title	Spanish Track	English Track
SEPTEMBER 2022	Origins of HIV, dissemination of the pandemic, immunopathogenesis	<b>Julià Blanco</b> , IrsiCaixa Research Institute Germans Trias i Pujol, Badalona, Spain.	<b>Ana Abecasis</b> , Universidade NOVA de Lisboa, Portugal.
	Natural history of the infection. Different types of clinical progression	<b>José Alcamí</b> , Instituto de Salud Carlos III, Madrid, Spain.	<b>Sharon Lewin</b> , The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
OCTOBER 2022	Laboratory diagnosis of HIV	<b>Beatriz Mothe</b> , IrsiCaixa Research Institute. University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Sarah Fidler</b> , Imperial College Health Care NHS Trust, London, UK.
	Epidemiology of HIV infection world-wide	<b>Juliana Reyes-Urueña</b> , Centre for Epidemiological Studies of Sexually Transmitted Disease and AIDS in Catalonia (CEEISCAT), Barcelona, Spain.	<b>Teymur Noori</b> , European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.
NOVEMBER 2022	Sexually Transmitted Diseases	<b>Martí Vall</b> , Infectious Diseases at the University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Jeanne Mrazz</b> , Infectious Diseases, University of Alabama at Birmingham, AL, USA.
	Pre-exposure antiretroviral prophylaxis	<b>Pep Coll</b> , IrsiCaixa Research Institute. University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Jean-Michel Molina</b> , University of Paris Diderot, Paris, France.



**HIV**  
FROM  
A to Z

Training the new  
**generation of HIV**  
physicians

Month	Title	Spanish Track	English Track
DECEMBER 2022	Human papillomavirus coinfection in HIV disease and related cancers	<b>Adrià Curran</b> , University Hospital Vall d'Hebron, Barcelona, Spain.	<b>Carmelina Cappello</b> , Homerton University Hospital, London, UK.
	Inflammation and immune activation in HIV infection	<b>Jorge Geffner</b> , Universidad de Buenos Aires, Argentina.	<b>Peter Hunt</b> , UCSF School of Medicine, San Francisco, USA.
JANUARY 2023	Opportunistic infections in HIV disease. Its management and prevention	<b>Brenda Crabtree</b> , Instituto Nacional de Ciencias Médicas Salvador Zubirán, México DF, México.	<b>Ole Kirk</b> , Dept of Clinical Medicine, Rigshospitalet, Copenhagen, Denmark.
	Current most frequent tumors. Management and prevention	<b>Valeria Fink</b> , Fundación Huésped, Buenos Aires, Argentina.	<b>Warren T. Phipps</b> , Fred Hutch Cancer Center, Seattle, WA, USA.
FEBRUARY 2023	Toxicity of ARV drugs in the current era (weight, neuropsych issues, metabolic profile)	<b>Arkaitz Imaz</b> , Infectious diseases, Bellvitge University Hospital, L'Hospitalet del Llobregat, Spain.	<b>Paul Sax</b> , Brigham and Women's Hospital, Division of Infectious Disease, Boston, MA, USA.
	Liver disease associated with HIV infection: nonalcoholic steatohepatitis (NAFLD/NASH)	<b>Juan M. Pericàs</b> , Vall d'Hebron University Hospital, Barcelona, Spain	<b>Mark Sulkowski</b> , Johns Hopkins University, Baltimore, MA, USA.



**HIV**  
FROM  
A to Z

Training the new  
**generation of HIV**  
physicians

Month	Title	Spanish Track	English Track
MARCH 2023	Liver disease associated with HIV infection: viral hepatitis C treatment and elimination	<b>Sabela Lens</b> , Hospital Clínic de Barcelona, Spain.	<b>Sabela Lens</b> , Hospital Clínic de Barcelona, Spain.
	HIV and COVID	<b>Josep M Miró</b> , Hospital Clinic, Barcelona, Spain.	<b>Monica Gandhi</b> , University California San Francisco, CA, USA.
APRIL 2023	Long-term complications and comorbidities in HIV infection	<b>Eugènia Negredo</b> , Infectious Diseases at the University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Patrick Mallon</b> , University College Dublin (UCD) and St. Vincent's University Hospital, Dublin, Ireland
	Liver disease associated with HIV infection: viral hepatitis B progress and pipeline	<b>Maria Buti</b> , University Hospital Vall d'Hebron, Barcelona, Spain.	<b>Jennifer Price</b> , University California San Francisco, CA, USA.
MAY 2023	Management of antiretroviral PK interactions	<b>José Moltó</b> , Infectious Diseases at the University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Saye Khoo</b> , Molecular and Clinical Pharmacology, University of Liverpool, UK.
	HIV resistance to antiretroviral therapy	<b>Roger Paredes</b> , IrsiCaixa Research Institute. University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Annemarie Wensing</b> , University Medical Center Utrecht, The Netherlands.



**HIV**  
FROM  
A to Z

Training the new  
**generation of HIV**  
physicians

Month	Title	Spanish Track	English Track
JUNE 2023	Antiretroviral treatment strategies. Initial treatment	<b>Josep M Llibre</b> , Infectious Diseases at the University Hospital Germans Trias i Pujol. Fight Infections Foundation, Badalona, Spain.	<b>Pedro Cahn</b> , Fundación Huésped, Buenos Aires, Argentina.
	Antiretroviral treatment strategies. Treatment switch and simplification	<b>Raquel Martin-Iguacel</b> , Infectious Diseases, Odense University Hospital, Denmark.	<b>Ann-Brit, Eg Hansen</b> , Rigshospitalet, Copenhagen, Denmark..
JULY 2023	Management of HIV in pregnant women	<b>Alexandra Compagnucci</b> , French institute of Health and Medical Research, INSERM, Paris, France.	<b>Rebecca Zash</b> , Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA.
	HIV paediatric pearls	<b>Clàudia Fortuny</b> , Dept. of Pediatrics, Hospital Sant Joan de Déu, Barcelona.	<b>Hermione Lyall</b> , Imperial College Health Care NHS Trust, London, UK.
AUGUST 2023	HIV eradication and cure	<b>Javier Martinez-Picado</b> , IrsiCaixa Research Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.	<b>Tae-Wook Chun</b> , National Institute of Allergy and Infectious Diseases. National Institutes of Health, Bethesda, Maryland, USA.
	Upcoming pipeline on new antiretrovirals and long-acting regimens. How the new ones will change treatment approaches	<b>José Ramón Arribas</b> , University Hospital La Paz, Madrid, Spain. (TBC)	<b>Chloe Orkin</b> , Royal London Hospital, London, UK.



This educational activity is supported by an independent educational grant from the following companies. The sponsors were not involved in the development of content or selection of faculty for this educational activity



MORE INFORMATION  
[www.fls-science.com](http://www.fls-science.com)

